CrkL antibody (AA 286-303)

Catalog No. ABIN3029484

Product Details anti-CrkL Antibody

Target: CrkL (CRKL) (V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like (CRKL))

Binding Specificity: AA 286-303

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CrkL antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogen: Amino acids 286-303 (FPFTHVKIFDPQNPDENE-human) were used as the immunogen for this CrkL antibody.

Isotype: IgG

Application Details

Application Notes: The stated application concentrations are suggested starting amounts. Titration of the CrkL antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Handling

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: -20 °C

Storage Comment: After reconstitution, the CrkL antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Target Details for CrkL

Target: CrkL (CRKL) (V-Crk Sarcoma Virus CT10 Oncogene Homolog (Avian)-Like (CRKL))

Alternative Name: CrkL (CRKL Products)

Synonyms: CRKL antibody, wu:fa55g05 antibody, wu:fj60e01 antibody, zgc:63469 antibody, 1110025F07Rik antibody, AA589403 antibody, AI325100 antibody, Crkol antibody, CRK like proto-oncogene, adaptor protein antibody, v-crk avian sarcoma virus CT10 oncogene homolog-like antibody, CRKL antibody, crkl antibody, Crkl antibody

Background: V-Crk sarcoma virus CT10 oncogene homolog(avian)-like), also called CrkL, encodes a 303-amino acid polypeptide with a predicted molecular mass of ~36 kD. While CrkL is not the human homolog of CRK, it is similar to protein-tyrosine kinases with SH2 and SH3 (src homology) domains. By fluorescence in situ hybridization,the gene is localized to chromosome 22q11, centromeric of the chronic myelogenous leukemia breakpoint region. Senechal et al.(1996)showed that CRKL becomes phosphorylated when overexpressed, activates Ras-dependent and JNK pathways, and transforms fibroblasts. The authors also found CrkL to be a substrate for the BCR-ABL tyrosine kinase, leading them to conclude that it is a tyrosine kinase and an oncogene. CrkLwas required for normal cellular responses to Fgf8, including survival and migration, Erk activation, and target gene expression.

UniProt: P46109

Pathways: Interferon-gamma Pathway, Neurotrophin Signaling Pathway, Signaling of Hepatocyte Growth Factor Receptor